Menopauza i hormonalna terapia zastępcza w cukrzycy
Piśmiennictwo
1.Szczeklik-Kumala Z.: Patofizjologia i klinika menopauzy u kobiet z cukrzycą. Medycyna Metaboliczna 2009: t. XIII, nr 1;78-85
2.Skałba P.: Hormonalna terapia zastępcza. Wyd. 2, PZWL 2004
3.Dunne P., Harris P., Keane L., Jenkins D., Wright AD.: Hormone replacement therapy and diabetes mellitus. Clinical Endocrinology 1996;44:615-620.
4.Lemay A., Dodin S., Cedrin I., Lemay L.: Phasic serum lipid excursions occur during cyclical oral conjugated oestrogens but not during transdermal oestradiol sequentially combined with oral medroxyprogesterone acetate. Clinical Endocrinology 1995;42:341-351
5.Nabulsi A., Folsom R., White A.: Association of hormone replacement therapy with various cardiovascular risk factors in post-menopausal women. New England Journal of medicine 1993;328:1069-1075
6.Manson J.: A prospective study of postpartum oestrogen therapy and subsequent incidence of non insulin dependent diabetes mellitus. Annals of Epidemiology 1992;2:665-673
7.Godsland I., Gansar K., Walton C., Cast M., Whitehead M., Wynn V., Stevenson J.: Insulin resistance, secretion and elimination in post-menopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993;42:846-853
8.Mann R., Lis Y., Chukwujindu J., Chanter D.: A study of the association between hormone replacement therapy, smoking and the occurrence of myocardial infarction in women. Journal of Clinical Epidemiology 1994;47:307-312
9.Skałba P.: Endokrynologia ginekologiczna. Wyd. 3, PZWL 2008
10.Ziegler R.: Diabetes Mellitus and bone metabolism. Hormone Metabolism and Research 1992;26 [Suppl.]:90-94
11.Saneshige S.: Spinal bone mineral density in the female population. Japanese Journal of Geriatrics 1992;29:864-873
12.Folsom A., Minic P., Sellers T., Hong C., Zheng W., Potter J.: Hormone replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. American Journal of Public Health 1995;85:1128-1131
13.Stanford J., Weiss N., Voigt L., Daling J., Habel L., Rossing M.: Combined oestrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. Jama 1995;274:137-142
14. Speroff L.: The risk of breast cancer with oral contraception and hormone replacement therapy. Womens Health Issues 1992, 2, 63-72
15.Colditz G., Hankinson S., Hunter D., Willett W., Manson J., Stampfer M., Hennekens C., Rosner B, Speizer F.: The use of oestrogens and progestins and the risk of breast cancer in postmenopausal women. New England Journal of Medicine 1995;332:1589-1593
16.Tatoń J., Czech A.: Diabetologia, Wyd 1, PZWL 2001
17.Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure. Diabetologia 1996;39:1554-1561
18. UK Prospective Diabetes Study [UKPDS] Group: Efficacy of atenolol and captopril in reducing the risk of macrovascular and microvascular complications in type 2 diabetes: UKPDAS 39, BMJ 1998;317:713-720
19.The six report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Inter Med 1997;157:2431-2446.
2.Skałba P.: Hormonalna terapia zastępcza. Wyd. 2, PZWL 2004
3.Dunne P., Harris P., Keane L., Jenkins D., Wright AD.: Hormone replacement therapy and diabetes mellitus. Clinical Endocrinology 1996;44:615-620.
4.Lemay A., Dodin S., Cedrin I., Lemay L.: Phasic serum lipid excursions occur during cyclical oral conjugated oestrogens but not during transdermal oestradiol sequentially combined with oral medroxyprogesterone acetate. Clinical Endocrinology 1995;42:341-351
5.Nabulsi A., Folsom R., White A.: Association of hormone replacement therapy with various cardiovascular risk factors in post-menopausal women. New England Journal of medicine 1993;328:1069-1075
6.Manson J.: A prospective study of postpartum oestrogen therapy and subsequent incidence of non insulin dependent diabetes mellitus. Annals of Epidemiology 1992;2:665-673
7.Godsland I., Gansar K., Walton C., Cast M., Whitehead M., Wynn V., Stevenson J.: Insulin resistance, secretion and elimination in post-menopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993;42:846-853
8.Mann R., Lis Y., Chukwujindu J., Chanter D.: A study of the association between hormone replacement therapy, smoking and the occurrence of myocardial infarction in women. Journal of Clinical Epidemiology 1994;47:307-312
9.Skałba P.: Endokrynologia ginekologiczna. Wyd. 3, PZWL 2008
10.Ziegler R.: Diabetes Mellitus and bone metabolism. Hormone Metabolism and Research 1992;26 [Suppl.]:90-94
11.Saneshige S.: Spinal bone mineral density in the female population. Japanese Journal of Geriatrics 1992;29:864-873
12.Folsom A., Minic P., Sellers T., Hong C., Zheng W., Potter J.: Hormone replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. American Journal of Public Health 1995;85:1128-1131
13.Stanford J., Weiss N., Voigt L., Daling J., Habel L., Rossing M.: Combined oestrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. Jama 1995;274:137-142
14. Speroff L.: The risk of breast cancer with oral contraception and hormone replacement therapy. Womens Health Issues 1992, 2, 63-72
15.Colditz G., Hankinson S., Hunter D., Willett W., Manson J., Stampfer M., Hennekens C., Rosner B, Speizer F.: The use of oestrogens and progestins and the risk of breast cancer in postmenopausal women. New England Journal of Medicine 1995;332:1589-1593
16.Tatoń J., Czech A.: Diabetologia, Wyd 1, PZWL 2001
17.Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure. Diabetologia 1996;39:1554-1561
18. UK Prospective Diabetes Study [UKPDS] Group: Efficacy of atenolol and captopril in reducing the risk of macrovascular and microvascular complications in type 2 diabetes: UKPDAS 39, BMJ 1998;317:713-720
19.The six report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Inter Med 1997;157:2431-2446.
